Published in Cancer Lett on March 14, 2017
The hallmarks of cancer. Cell (2000) 113.05
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell (2007) 22.89
Apoptosis: a review of programmed cell death. Toxicol Pathol (2007) 17.92
Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med (1996) 7.32
Cancer Statistics, 2017. CA Cancer J Clin (2017) 4.77
Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer (2004) 4.43
The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. J Clin Invest (2011) 4.41
Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer (2014) 3.70
Resistin, an adipokine with potent proinflammatory properties. J Immunol (2005) 3.63
Induction of apoptosis by cancer chemotherapy. Exp Cell Res (2000) 3.51
Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev (2011) 3.04
Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol (2012) 2.47
Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J Clin Pathol (2011) 2.33
Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med (2013) 2.20
Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin Cancer Res (2006) 2.11
Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J Natl Cancer Inst (2010) 1.89
Differences in the tumor microenvironment between African-American and European-American breast cancer patients. PLoS One (2009) 1.72
Caspase control: protagonists of cancer cell apoptosis. Exp Oncol (2012) 1.69
Caspases and cancer. Cell Death Differ (2011) 1.56
Apoptosis, chemoresistance, and breast cancer: insights from the MCF-7 cell model system. Exp Biol Med (Maywood) (2003) 1.53
Apoptosis and cancer chemotherapy. Cell Tissue Res (2000) 1.41
The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays. Mol Cancer Ther (2006) 1.29
Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities. CA Cancer J Clin (2016) 1.28
Integrin signaling in cancer cell survival and chemoresistance. Chemother Res Pract (2012) 1.26
Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells. Cell Signal (2013) 1.24
Adipocytokines and breast cancer risk. Chin Med J (Engl) (2007) 1.23
Oct-4 and Nanog promote the epithelial-mesenchymal transition of breast cancer stem cells and are associated with poor prognosis in breast cancer patients. Oncotarget (2014) 1.20
Relationship of serum adiponectin and resistin levels with breast cancer risk. J Korean Med Sci (2007) 1.19
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol (2016) 1.18
Breast cancer stem cells and epithelial mesenchymal plasticity - Implications for chemoresistance. Cancer Lett (2013) 1.18
Resistance to endocrine therapy: are breast cancer stem cells the culprits? J Mammary Gland Biol Neoplasia (2009) 1.02
Adipocytokine resistin and breast cancer risk. Breast Cancer Res Treat (2010) 1.02
Resistin expression in breast cancer tissue as a marker of prognosis and hormone therapy stratification. Gynecol Oncol (2012) 0.99
STAT3 signaling is activated preferentially in tumor-initiating cells in claudin-low models of human breast cancer. Stem Cells (2014) 0.99
Resistin and interleukin-6 exhibit racially-disparate expression in breast cancer patients, display molecular association and promote growth and aggressiveness of tumor cells through STAT3 activation. Oncotarget (2015) 0.96
Understanding breast cancer stem cell heterogeneity: time to move on to a new research paradigm. BMC Med (2013) 0.95
Breast cancer stem cells and their role in resistance to endocrine therapy. Horm Cancer (2011) 0.95
Triple-negative breast cancer: treatment challenges and solutions. Breast Cancer (Dove Med Press) (2016) 0.95
Cancer stem cells and chemoresistance: The smartest survives the raid. Pharmacol Ther (2016) 0.93
Differentially expressed transcripts and dysregulated signaling pathways and networks in African American breast cancer. PLoS One (2013) 0.90
Nicotine promotes apoptosis resistance of breast cancer cells and enrichment of side population cells with cancer stem cell-like properties via a signaling cascade involving galectin-3, α9 nicotinic acetylcholine receptor and STAT3. Breast Cancer Res Treat (2014) 0.88
p-21 activated kinase 4 (PAK4) maintains stem cell-like phenotypes in pancreatic cancer cells through activation of STAT3 signaling. Cancer Lett (2015) 0.84
Evaluation of diagnostic and predictive value of serum adipokines: Leptin, resistin and visfatin in postmenopausal breast cancer. Obes Res Clin Pract (2015) 0.83
The Role of MicroRNAs in the Chemoresistance of Breast Cancer. Drug Dev Res (2015) 0.83
Resistin promotes the expression of vascular endothelial growth factor in ovary carcinoma cells. Int J Mol Sci (2013) 0.83
Resistin's, obesity and insulin resistance: the continuing disconnect between rodents and humans. J Endocrinol Invest (2015) 0.83
Chemoresistance is associated with increased cytoprotective autophagy and diminished apoptosis in bladder cancer cells treated with the BH3 mimetic (-)-Gossypol (AT-101). BMC Cancer (2015) 0.82
Gemcitabine triggers angiogenesis-promoting molecular signals in pancreatic cancer cells: Therapeutic implications. Oncotarget (2015) 0.82
Pygo2 activates MDR1 expression and mediates chemoresistance in breast cancer via the Wnt/β-catenin pathway. Oncogene (2016) 0.81
Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK. Br J Cancer (2017) 0.78
Human resistin in chemotherapy-induced heart failure in humanized male mice and in women treated for breast cancer. Endocrinology (2013) 0.78
Effect of oncological treatment on serum adipocytokine levels in patients with stage II-III breast cancer. Mol Clin Oncol (2016) 0.78
Tumor microenvironment-mediated chemoresistance in breast cancer. Breast (2016) 0.78
Resistin, a fat-derived secretory factor, promotes metastasis of MDA-MB-231 human breast cancer cells through ERM activation. Sci Rep (2016) 0.78
Metronomics in the neoadjuvant and adjuvant treatment of breast cancer. Cancer Lett (2017) 0.77
Elevated Resistin Gene Expression in African American Estrogen and Progesterone Receptor Negative Breast Cancer. PLoS One (2016) 0.77
Resistin and Insulin Resistance: A Link Between Inflammation and Hepatocarcinogenesis. Asian Pac J Cancer Prev (2015) 0.77
Circulating resistin levels and obesity-related cancer risk: A meta-analysis. Oncotarget (2016) 0.76
Circulating Resistin Levels and Risk of Colorectal Cancer: A Meta-Analysis. Biomed Res Int (2016) 0.76
Glucose Metabolism Reprogrammed by Overexpression of IKKε Promotes Pancreatic Tumor Growth. Cancer Res (2016) 0.76
Breast tumor stroma: A driving force in the development of resistance to therapies. Chem Biol Drug Des (2017) 0.76
Biological basis of cancer health disparities: resources and challenges for research. Am J Cancer Res (2017) 0.76
Prevalence of Insulin Resistance, Metabolic Syndrome, and Type 2 Diabetes in Canadian Women at High Risk for Breast Cancer. Breast J (2017) 0.76
Silver nanoparticles protect human keratinocytes against UVB radiation-induced DNA damage and apoptosis: potential for prevention of skin carcinogenesis. Nanomedicine (2015) 0.86
Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK. Br J Cancer (2017) 0.78
Epigenetic Basis of Cancer Health Disparities: Looking Beyond Genetic Differences. Biochim Biophys Acta (2017) 0.76